文献速递药物不良反应与药物警戒

MMP-9-1562C/T多态性TT基因型可能是急性缺血性卒中溶栓治疗后出血并发症的风险因素

TT genotype of the MMP-9-1562C/T polymorphism may be a risk factor for thrombolytic therapy-induced hemorrhagic complications after acute ischemic stroke.
PubMed 文献 · Pharmacotherapy · 2021-05-27

本研究纳入166例接受rtPA治疗的急性缺血性卒中患者,检测MMP-2、MMP-9和TIMP-2基因多态性,评估3个月mRS评分及住院期间不良事件。结果显示所选多态性与rtPA疗效无显著关联,但MMP-9-1562C/T的TT基因型与颅内出血及脑实质血肿2型显著相关。

要点

  • MMP-9-1562C/T的TT基因型与rtPA后颅内出血风险增加相关(p=0.047)。
  • TT基因型与脑实质血肿2型风险增加相关(p=0.011)。
  • 所选多态性与3个月mRS评分改善无显著关联。

核心结论

  • MMP-9-1562C/T多态性的TT基因型可能是急性缺血性卒中后rtPA诱导出血并发症的风险因素。

研究设计与样本

  • 研究纳入166例接受rtPA治疗的急性缺血性卒中患者,采用实时PCR和PCR-RFLP法对MMP-2、MMP-9和TIMP-2基因的7个多态性位点进行基因分型。
  • 卒中后3个月采用改良Rankin量表评估恢复情况,良好结局定义为评分0-1,不良结局定义为评分2-6。
  • 住院期间随访rtPA相关不良事件。

主要发现

  • 所选多态性的基因型和等位基因与rtPA治疗反应(通过mRS评分下降衡量)之间无显著关联。
  • MMP-9-1562C/T多态性TT基因型患者颅内出血发生率显著更高(p=0.047)。
  • MMP-9-1562C/T多态性TT基因型患者脑实质血肿2型发生率显著更高(p=0.011)。
  • rtPA后发生颅内出血的患者更可能携带TIMP-2-303C/T多态性TT基因型和MMP-9-1562C/T多态性TT基因型(p<0.001)。

临床怎么用

  • 对于急性缺血性卒中拟接受rtPA治疗的患者,可考虑检测MMP-9-1562C/T基因型以辅助评估出血风险。
  • 携带MMP-9-1562C/T TT基因型的患者溶栓后需加强出血监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Levels of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) influence recombinant tissue plasminogen activator (rtPA) therapy response in patients with acute ischemic stroke (AIS). Serum levels of MMPs and TIMPs along with the expression of genes coding these proteins are related to the recovery and appearance of adverse effects (AE) after AIS. Consequently, it is important to explore whether polymorphisms in regulatory sequences of MMPs and TIMPs are associated with rtPA response in AIS patients. OBJECTIVES: To determine whether selected polymorphic variants within MMP-2, MMP-9, and TIMP-2 genes may influence rtPA therapy response with regard to outcomes in patients with AIS and the occurrence of AE. METHODS: Our study included 166 patients suffering AIS, treated with rtPA. Patients' recovery was estimated using the Modified Rankin Scale (mRS) 3 months after the AIS occurred. Favorable outcome was defined with scores 0-1 and poor outcome with scores 2-6. Genotyping was performed using real-time PCR (rs243866, rs243865, rs243864, rs2277698, and rs8179090) and PCR-RFLP (rs2285053, rs3918242) methods. Additionally, rtPA AE were followed during the hospitalization. RESULTS: There was no significant association between genotypes and alleles of selected polymorphisms and rtPA therapy response measured through the decrease of the mRS score in patients with AIS. Intracranial hemorrhage, as well as parenchymal hematoma type 2, was significantly more frequent in patients with TT genotype of the MMP-9-1562C/T polymorphism (p = 0.047, p = 0.011, respectively). Patients with intracranial hemorrhages after rtPA were significantly more likely to have the TT genotype of TIMP-2-303C/T polymorphism and the TT genotype of MMP-9-1562C/T polymorphism (p < 0.001). CONCLUSION: TT genotype of the MMP-9-1562C/T polymorphism may be a risk factor for rtPA-induced hemorrhagic complications after AIS.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Dusanovic Pjevic M, Jekic B, Beslac Bumbasirevic L, et al. TT genotype of the MMP-9-1562C/T polymorphism may be a risk factor for thrombolytic therapy-induced hemorrhagic complications after acute ischemic stroke. Pharmacotherapy. 2021. PMID: 33942334. doi:10.1002/phar.2532

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。